CORRESP Filing
Enveric Biosciences, Inc.
Date: Dec. 8, 2025 · CIK: 0000890821 · Accession: 0001493152-25-026563
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290580
Letter
RE: Enveric Biosciences, Inc.
December 8, 2025
VIA EDGAR
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Registration Statement on Form S-3, as amended
(File No. 333-290580)
Acceleration Request
Requested Date: December 8, 2025
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), Enveric Biosciences, Inc. (the "Company") requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Adin J. Tarr of Greenberg Traurig, LLP at (602) 445-8058 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
Enveric Biosciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm December 8, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Enveric Biosciences, Inc. Registration Statement on Form S-3, as amended (File No. 333-290580) Acceleration Request Requested Date: December 8, 2025 Requested Time: 4:30 p.m., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), Enveric Biosciences, Inc. (the "Company") requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission. Please call Adin J. Tarr of Greenberg Traurig, LLP at (602) 445-8058 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, Enveric Biosciences, Inc. By: /s/ Joseph Tucker Name: Joseph Tucker, Ph.D. Title: Chief Executive Officer